What happened
Natera, Inc. (NASDAQ: NTRA) Chief Financial Officer Michael Burkes Brophy sold 3,084 shares of common stock from Oct. 28 to Oct. 30. The sales brought in about $1.31 million.
The Form 4 reports three sales. On Oct. 28, Brophy sold 313 shares at $425.32 and 865 shares at $426.87. On Oct. 30, Brophy sold 1,906 shares at $425.55. Brophy holds the remaining 46,574 shares directly.
The Form 4 says the sales were made under a Rule 10b5-1 trading plan that Brophy adopted on June 9, 2025 and modified on Sept. 10, 2025. Both dates fall more than a year before the sales.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 3,084 shares | SEC Form 4 | |
| Sale price range | $425.32 to $426.87 per share | SEC Form 4 | |
| Total sale proceeds | about $1.31 million | SEC Form 4 | |
| Shares held after the sales | 46,574 shares | SEC Form 4 | |
| Share of pre-trade holding sold | 6.2% | Calculated from SEC Form 4 |
Read more: Natera (NTRA) company research
Why it matters
The sales trimmed Brophy's holding by 6.2%, by OptimistFi's calculation from the 49,658 shares held before the trades. The trades fall under a plan that predates them, which limits any reading of them as a verdict on the business.
The seller is Natera's Chief Financial Officer, so the Form 4 shows a senior finance executive selling a minority of directly held common stock while keeping the rest. The sales came in three separate lots across two trading days, each reported as a sale of common stock.
OptimistFi has argued that Natera's value depends on proving that clinical adoption and reimbursement can keep scaling while rapid test growth turns into durable cash generation. A CFO's plan sale does not bear on either test, so the sale leaves the investment case unchanged.
The same plan status cuts both ways. Sales under a Rule 10b5-1 plan may be routine, so they say little about business performance or valuation, whether read as a warning or as comfort. Brophy also keeps most of the position.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Natera's next quarterly report is the next test of the case. Evidence there that adoption and reimbursement are still scaling and that growth is turning into cash would strengthen it, and a stall in either would weaken it.
More from OptimistFi
From OptimistFi Perps
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
Sources
- SEC Form 4, Natera, Inc., Michael Burkes Brophy — Statement of changes in beneficial ownership signed Oct. 30, 2026, reporting three open-market sales under a Rule 10b5-1 plan.
Explore OptimistFi research on Natera, Inc.: https://optimistfi.com/stocks/NTRA
Browse Natera, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Natera, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
